Advances in Understanding the Molecular Mechanisms of the Cardiovascular Toxicity of Targeted Cancer Therapies

doi:10.3969/j.issn.1007-9572.2018.00.246

Abstract

Abstract: Molecular targeted therapy is a revolutionary approach in cancer treatment that improves the quality of life of patients and prolongs patient life.However，targeted drugs often have cardiovascular toxicity.In this article，we review the adverse cardiovascular events associated with targeted therapies，including cardiac dysfunction and heart failure，arrhythmias，pulmonary hypertension，hypertension，arterial and venous ischemia and hemorrhage.We also summarize the mechanisms that contribute to the cardiovascular side effects of target drugs.

Key words: Neoplasms, Antineoplastic agents, Cardiovascular diseases, Toxic side effects, Review

摘要： 分子靶向治疗是癌症治疗革命性改变，其提高了患者生活质量，延长了患者寿命，但此类药物多具有心血管毒性。本文总结了与靶向治疗相关的心血管不良事件，包括心功能障碍、心力衰竭、心律失常、肺动脉高压、高血压以及动脉和静脉缺血、出血，总结了造成心血管毒副作用的相关机制，旨在为今后的研究提供帮助。

关键词: 肿瘤, 抗肿瘤药, 心血管疾病, 毒副作用, 综述

QI Hong-tao,PENG Zong-yu. Advances in Understanding the Molecular Mechanisms of the Cardiovascular Toxicity of Targeted Cancer Therapies[J]. Chinese General Practice, 2018, 21(27): 3403-3406. DOI: 10.3969/j.issn.1007-9572.2018.00.246.
齐洪涛,彭宗玉. 癌症靶向治疗后心血管毒副作用的分子机制研究进展[J]. 中国全科医学, 2018, 21(27): 3403-3406. DOI: 10.3969/j.issn.1007-9572.2018.00.246.

References

［1］CHANG H M，MOUDGIL R，SCARABELLI T，et al.Cardiovascular complications of cancer therapy：best practices in diagnosis，prevention，and management：part 1［J］.J Am Coll Cardiol，2017，70（20）：2536-2551.DOI：10.1016/j.jacc.2017.09.1096.3405
［2］ESCALANTE C P，CHANG Y C，LIAO K，et al.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents［J］.Support Care Cancer，2016，24（9）：4057–4074 .DOI：10.1007/s00520-016-3310-3.3405
［3］CHOUEIRI T K，MAYER E L，JE Y，et al.Congestive heart failure risk in patients with breast cancer treated with bevacizumab［J］.J Clin Oncol，2011，29（6）：632–638.DOI：10.1200/JCO.2010.31.9129.3405
［4］BIANCO C M，Al-KINDI S G，OLIVEIRA G H，et al.Advanced heart failure therapies for cancer therapeutics– related cardiac dysfunction［J］.Heart Fail Clin，2017，13（2）：327-336.DOI：10.1016/j.hfc.2016.12.005.3405
［5］KROP I E，SUTER T M，DANG C T，et al.Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as （neo）adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer［J］.J Clin Oncol，2015，33（10）：1136–1142.DOI：10.1200/JCO.2014.58.7782.3405
［6］SENDUR M A，AKSOY S，ALTUNDAG K.Cardiotoxicity of novel HER2-targeted therapies［J］.Curr Med Res Opin，2013，29（8）：1015-1024.DOI：10.1185/03007995.2013.807232.3405
［7］BLOOM M W，HAMO C E，CARDINALE D，et al.Cancer therapy-related cardiac dysfunction and heart failure：part 1：definitions，pathophysiology，risk factors，and imaging［J］.Circ Heart Fail，2016，9（1）：e002661.DOI：10.1161/CIRCHEARTFAILURE.115.002661.3405
［8］KLOTH J S，PAGANI A，VERBOOM M C，et al.Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors［J］.Br J Cancer，2015，112（6）：1011–1016.DOI：10.1038/bjc.2015.82.3406
［9］TAMARGO J，CABALLERO R，DELPON E.Cancer chemotherapy and cardiac arrhythmias：a review［J］.Drug Saf，2015，38（2）：129-152.DOI：10.1007/s40264-014-0258-4.3406
［10］FRADLEY M G，PINILLA-IBARZ J.Arrhythmic complications of tyrosine kinase inhibitors［J］.Future Cardiol，2015，11（4）：395-399.DOI：10.2217/FCA.15.42.3406
［11］BUZA V，RAJAGOPALAN B，CURTIS A B.Cancer treatment-induced arrhythmias focus on chemotherapy and targeted therapies［J］.Circ Arrhythm Electrophysiol，2017，10（8）：e005443.DOI：10.1161/CIRCEP.117.005443.3406
［12］MARKMAN T M，NAZARAN S.Arrhythmia and electrophysiological effects of chemotherapy：a review［J］.Oncology，2016，91（2）：61-68.DOI：10.1159/000446374.3406
［13］VIGANEGO F，SINGH R，FRADLEY M G.Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation［J］.Curr Cardiol Rep，2016，18（6）：52.DOI：10.1007/s11886-016-0730-0.3406
［14］SHAH N P，WALLIS N，FARBER H W，et al.Clinical features of pulmonary arterial hypertension in patients receiving dasatinib［J］.Am J Hematol，2015，90（11）：1060–1064.DOI：10.1002/ajh.24174.3406
［15］TAJIRI K，AONUMA K，SEKINE I.Cardiovascular toxic effects of targeted cancer therapy［J］.Jpn J Clin Oncol，2017，5（20）：1-7.DOI：10.1093/jjco/hyx071.3406
［16］MCGEE M，WHITEHEAD N，MARTIN J，et al.Drug-associated pulmonary arterial hypertension［J］.Clin Toxicol（Phila），2018，6（5）：1-9.DOI：10.1080/15563650.2018.1447119.3406
［17］GUIGNABERT C，PHAN C，SEFERIAN A，et al.Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertention［J］.J Clin Invest，2016，126（9）：3207-3218.DOI：10.1172/JCI86249.3406
［18］SUNDARARAJAN S，KUMAR A，POONGKUNRAN M，et al.Cardiovascular adverse effects of targeted antiangiogenic drugs：mechanisms and management［J］.Future Oncol，2016，12（8）：1067-1080.DOI：10.2217/fon.16.4.3406
［19］MOSLEHI J J，DEININGER M.Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia［J］.J Clin Oncol，2015，33（35）：4210-4218.DOI：10.1200/JCO.2015.62.4718.3406
［20］ABDEL-QADIR H，ETHIER J L，LEE D S，et al.Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy：a systematic review and meta-analysis［J］.Cancer Treat Rev，2017，53：120-127.DOI：10.1016/j.ctrv.2016.12.002.3406
［21］BOSSAER J B，GERACI S A，CHAKRABORTY K.Cardiovascular toxicity and management of targeted cancer therapy［J］.Am J Med Sci，2016，351（5）：535-543.DOI：10.1016/j.amjms.2016.02.023.3406
［22］HERRMANN J，YANG E H，IIIESCU C A，et al.Vascular toxicities of cancer therapies：the old and new——an evolving avenue［J］.Circulation，2016，133（13）：1272-1289.DOI：10.1161/CIRCULATIONAHA.115.018347.3406
［23］RANPURA V，HAPANI S，CHUANG J，et al.Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients：a meta-analysis of randomized controlled trials［J］.Acta Oncol，2010，49（3）：287–297.DOI：10.3109/02841860903524396.3406
［24］QI W X，SHEN Z，TANG L N，et al.Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors：an up-to-date meta-analysis［J］.Crit Rev Oncol Hematol，2014，92（2）：71–82.DOI：10.1016/j.critrevonc.2014.04.004.3406
［25］HAGUET H，DOUXFILS J，MULLIER F.Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors：a systematic review and meta-analysis［J］.Expert Opin Drug Saf，2017，16（1）：5-12.DOI：10.1080/14740338.2017.1261824.3406
［26］WINNIK S，LOHMANN C，SICILIANI G，et al.Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis—implications for cardiovascular safety［J］.Int J Cardiol，2013，168（3）：2453–2461.DOI：10.1016/j.ijcard.2013.03.010.3406
［27］LOREN C P，ASLAN J E，RIGG R A，et al.The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif（ITAM） signaling，platelet activation and aggregate formation under shear［J］.Thromb Res，2015，135（1）：155–160.DOI：10.1016/j.thromres.2014.11.009.3406
［28］GOPAL S，MILLER K B，JAFFE I Z.Molecular mechanisms for vascular complications of targeted cancer therapies［J］.Clin Sci，2016，130（20）：1763-1779.DOI：10.1042/CS20160246.3406
［29］HAPANI S，SHER A，CHU D，et al.Increased risk of serious hemorrhage with bevacizumab in cancer patients：a meta-analysis［J］.Oncology，2010，79（1/2）：27–38.DOI：10.1159/000314980.3406
［30］HANG X F，XU W S，WANG J X，et al.Risk of high-grade bleeding in patients with cancer treated with bevacizumab：a meta-analysis of randomized controlled trials［J］.Eur J Clin Pharmacol，2011，67（6）：613–623.DOI：10.1007/s00228-010-0988-x.3406
［31］HENNING R J，HARBISON R D.Cardio-oncology：cardiovascular complications of cancer therapy［J］.Future Cardiol，2017，13（4）：379-396.DOI：10.2217/fca-2016-0081.3406
［32］KILICKAP S，ABALI H，CELIK I.Bevacizumab，bleeding，thrombosis，and warfarin［J］.J Clin Oncol，2003，21（18）：3542.DOI：10.1200/JCO.2003.99.046.3406

[1]	YANG Xu, FAN Jieting, SONG Hongyan, FENG Panpan, HAO Jingyu, YAO Mi. Risk Assessment and Communication Strategies for Cardiovascular Diseases in Primary Care [J]. Chinese General Practice, 2026, 29(10): 1294-1299.
[2]	Chinese Rehabilitation Medicine Association Community Rehabilitation Working Committee. Expert Consensus on Perioperative Nutritional Management for Liver Cancer Based on the Enhanced Recovery after Surgery Concept (2025) [J]. Chinese General Practice, 2026, 29(08): 953-964.
[3]	PEI Zhiyi, ZHANG Xiaoxin, LIN Jiayi, ZHANG Xiangyi, KANG Xiaofeng. Systematic Review of the Quality and Application of Patient Decision Aids in Cardiovascular Disease Based on IPDAS 4.0 Criteria [J]. Chinese General Practice, 2026, 29(07): 945-952.
[4]	YAO Wenjing, WANG Cuifeng, GAO Jinliang, REN Meiying, JING Xuefen, FU Yuhua. Autophagy Related Proteins Beclin-1 and LC3-ⅡExpression in Lung Cancer Metaststic Pleural Effusion [J]. Chinese General Practice, 2026, 29(05): 623-630.
[5]	ZHOU Rui, JIN Yue, LIU Tingting, CAI Kerun, CUI Yiyuan, LI Sicong, LIU Lixing, FENG Li, the Working Group for the Clinical Practice Guideline for the Secondary Bone Malignancy with Integrated Traditional Chinese and Western Medicine. Guidelines for Diagnosis and Treatment of Secondary Malignant Tumors of Bone Combined with Traditional Chinese and Western Medicine [J]. Chinese General Practice, 2026, 29(04): 423-435.
[6]	FAN Zhuanzhuan, LI Wenting, MA Guoliang. Relationship between the Chinese Visceral Adipose Index and Cardiovascular Disease in Postmenopausal Women: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(02): 180-187.
[7]	ZHANG Shu, CHENG Yu, WU Shouling, CHEN Shuohua, WU Yuntao. The Impact of Cumulative Plasma Atherogenic Index Exposure on Incident Cardiovascular Disease in Non-Diabetic Individuals: a Cohort Study [J]. Chinese General Practice, 2025, 28(36): 4558-4565.
[8]	ZHANG Ying, LIAO Xiaoyang, YANG Hanfei, YU Yongjun, LIU Lidi, JIA Yu, SHEN Can, LI Xiao, HUANG Chuanying, YANG Rong. Interpretation of the 2024 International Society of Hypertension Position Paper on Innovations in Blood Pressure Measurement and Reporting Technology and Its Implications for China [J]. Chinese General Practice, 2025, 28(36): 4541-4549.
[9]	ZHANG Hui, LUO Miaomiao, YU Xiaohang, LIN Xin, YE Lina, TANG Xuan, LI Jiaxue, XIE Xinyu, LAI Li, FENG Yan, LIU Yonghui, CHEN Weigang. The Application Value of a Novel Cell Collector for the Esophagus in Screening for Esophageal Lesions [J]. Chinese General Practice, 2025, 28(35): 4487-4493.
[10]	Community Rehabilitation Working Committee of Chinese Rehabilitation Medicine Association. Chinese Expert Consensus on Constipation Screening and Assessment for Community Cancer Patients (2025 Edition) [J]. Chinese General Practice, 2025, 28(34): 4249-4257.
[11]	ZHAO Zhuo, WANG He. Research Progress on the Mechanism of HIF-2α in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(33): 4241-4248.
[12]	Community Rehabilitation Working Committee of Chinese Rehabilitation Medicine Association. Chinese Expert Consensus on Community-based Cancer-related Fatigue Management (2025 Edition) [J]. Chinese General Practice, 2025, 28(33): 4117-4124.
[13]	LIU Mingbo, HE Xinye, YANG Xiaohong, WANG Zengwu. Interpretation of Report on Cardiovascular Health and Diseases in China 2024 [J]. Chinese General Practice, 2025, 28(32): 3989-4008.
[14]	ZHANG Jia, WANG Hairong, ZHAO Jing, SU Yifan. Influencing Factors of Screening Behavior of First-degree Relatives of Lung Cancer Patients Based on Logistic Regression and Decision Tree Model [J]. Chinese General Practice, 2025, 28(31): 3961-3967.
[15]	LI Jingling, LIU Ning, GUO Jun. Methodological Quality and Metrological Characteristics of Palliative Care Quality Assessment Tools for Cancer Patients: a Systematic Evaluation Based on COSMIN [J]. Chinese General Practice, 2025, 28(31): 3981-3988.